机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China.四川大学华西医院[2]Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China.四川大学华西医院[3]Department of Cardiovascular and Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China.四川大学华西医院[4]Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China.四川大学华西医院[5]Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China.四川大学华西医院
The role of statins in preventing prostate cancer is currently a controversial issue. The aim of this review is to investigate the effects of statins use on prostate cancer risk. Electronic databases (the Cochrane Library, PubMed, Medline, Embase, Web of Science, and ClinicalTrials.gov) were searched systematically up to April, 2015. Weighted averages were reported as relative risk (RR) with 95% confidence intervals (CIs). Statistic heterogeneity scores were assessed with the standard Cochran's Q test and I(2) statistic. The pooled estimates of randomized controlled trials (RCTs) and retrospective studies suggest that statins have a neutral effect on total prostate cancer (RR = 1·02, 95% CI: 0·90-1·14; and RR = 0·91, 95% CI: 0·79-1·02, respectively). This research provides no evidence to suggest that the use of statins for cholesterol lowering is beneficial for the prevention of low-grade or localized prostate cancer, although a plausible association between statins use and the reduction risk of advanced (RR = 0·87, 95% CI: 0·82-0·91) or high-grade prostate cancer (RR = 0·83, 95% CI: 0·66-0·99) is observed. Furthermore, it shows that prostate cancer risk does not statistically significant benefit from long-term statins use.
基金：
National Natural Science Foundation of China (Grant no. 81370855, 81200551),
and has received a grant from Foundation of Science & Technology Department of Sichuan Province (Grant no.
2013SZ0006). YL has received a research grant from the Prostate Cancer Foundation Young Investigator Award
2013, the National Natural Science Foundation of China (Grant no. 81300627), and a grant from Foundation of
Science & Technology Department of Sichuan Province (Grant no. 2015SZ0230).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|2 区综合性期刊
小类|2 区综合性期刊
最新[2023]版：
大类|2 区综合性期刊
小类|2 区综合性期刊
第一作者：
第一作者机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China.[2]Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China.[2]Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China.
推荐引用方式(GB/T 7714)：
Tan Ping,Wei Shiyou,Tang Zhuang,et al.LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies.[J].Scientific reports.2016,6:24521.doi:10.1038/srep24521.
APA：
Tan Ping,Wei Shiyou,Tang Zhuang,Gao Liang,Zhang Chen...&Wei Qiang.(2016).LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies..Scientific reports,6,
MLA：
Tan Ping,et al."LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies.".Scientific reports 6.(2016):24521
